

Ovarian Cancer Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (PARP, PD-L1 Inhibitors , Angiogenesis), By Major Markets (U.S., U.K., Germany, Spain, Italy, France, Japan), And Segment Forecasts, 2016 - 2022

<https://marketpublishers.com/r/ODE5778F46DEN.html>

Date: May 2018

Pages: 94

Price: US\$ 5,950.00 (Single User License)

ID: ODE5778F46DEN

Abstracts

This report can be delivered to the clients within 48 hours

The global ovarian cancer drugs market size is expected to be valued at USD 4.5 billion by 2022, as per a new report by Grand View Research, Inc., expanding at a CAGR of 23.7% during the forecast period. The growth of the market is largely driven by factors such as increased adoption of novel drugs and presence of strong pipeline. Rising incidence of ovarian cancer due to growing geriatric population and unhealthy lifestyles is providing an upthrust to the market.

Ovarian cancer accounts for 3.0% of all malignant tumors among women and 6.0% of all female deaths due to cancer. Ovarian cancer accounted for 235,200 new cases and 140,000 deaths worldwide in 2016 with the highest incidence being reported in North America and Europe.

Introduction of non-platinum based PARP inhibitors and VEGF inhibitors in second and third-line settings has changed the treatment regime for ovarian cancer dramatically. Several biologic and small-molecule therapies including antibody drug conjugates (ADC) in development are estimated to have a major impact on ovarian cancer treatment spectrum.

Further key findings from the report suggest:

EU5 is projected to be the second largest market with more than 10.0% share in 2022, owing to increasing ovarian cancer incidence and approval of PARP inhibitors

Key players in the industry are focusing on collaborations for development, broader product portfolios, and regional expansion in emerging markets to increase their market share

Combination regimens and pipeline breakthroughs, specifically those including checkpoint inhibitors such as Roche's Tecentriq and Pfizer's Bavencio, are poised to be the upcoming milestones for ovarian cancer treatment

PARP inhibitors are anticipated to be the fastest growing drug class in the ovarian cancer market through the forecast period. Factors such as continued uptake of approved PARP inhibitors owing to their superior efficacy, long treatment duration, and considerable number of treatment opportunities in first-line advanced settings are likely to propel the growth of the drug class.

Although angiogenesis inhibitors accounted for the majority of shares in the market in 2016, the drug class is expected to capture a marginal share in 2022 owing to increasing competition from PARP inhibitors and novel pipeline products

Out of 78 drugs in the pipeline for ovarian cancer, 11 drugs are in Phase III, 29 in Phase II and the remaining in Phase I and pre-clinical trials

A greater understanding of tumor microenvironment is estimated to occur, which would further drive successful development of new patient-specific therapies through the forecast period

Late-stage pipeline includes novel drugs such as ImmunoGen's mirvetuximab soravtansine and Vascular Biogenics' VBL-111.

Contents

CHAPTER 1 RESEARCH METHODOLOGY

- 1.1. Information Procurement
- 1.2. Information or Data Analysis
 - 1.2.1 Market Formulation & Validation

CHAPTER 2 EXECUTIVE SUMMARY

CHAPTER 3 DISEASE PRIMER AND EPIDEMIOLOGY

- 3.1. Disease Primer and Epidemiology
 - 3.1.1. Current Prevalence Rate and Incidence Rate for Seven Major Markets (U.S., Japan, EU5)

CHAPTER 4 GLOBAL OVARIAN CANCER DRUGS MARKET OVERVIEW

- 4.1 Major Therapeutic Classes for Ovarian Cancer
- 4.2 Market, by Therapeutic Class
- 4.3 Sales Performance, by Therapeutic Class (2016 - 2022)
 - 4.3.1. PARP Inhibitors
 - 4.3.2. Angiogenesis Inhibitors
 - 4.3.3. PD-L1 Inhibitors
- 4.4 Market Size and Forecast (2016- 2022)
- 4.5 Market Size and Forecast, by Seven Major Markets (2016- 2022)
 - 4.5.1 U.S., Sales by Therapeutic Class (2016 - 2022)
 - 4.5.2 U.K., Sales by Therapeutic Class (2016 - 2022)
 - 4.5.3 Germany, Sales by Therapeutic Class (2016 - 2022)
 - 4.5.4 France, Sales by Therapeutic Class (2016 - 2022)
 - 4.5.5 Italy, Sales by Therapeutic Class (2016 - 2022)
 - 4.5.6 Spain, Sales by Therapeutic Class (2016 - 2022)
 - 4.5.7 Japan, Sales by Therapeutic Class (2016 - 2022)
- 4.6 Market Share Distribution, by Company (2016- 2022)
- 4.7 Market Dynamics and Brand Strategies
- 4.8 Patent Expiry Analysis
- 4.9 Ovarian Cancer Market: Drivers and Restraints
 - 4.9.1 Market Drivers
 - 4.9.2 Market Restraints

4.10. M&A, Deal Landscape (2013-2017 YTD)

4.10.1 Mergers & Acquisitions

4.10.2 Deals Landscape

4.11. Evolution of Biosimilars

4.12. Emerging Markets

4.13. Pricing and Reimbursement Scenario

4.14. Ovarian Cancer Sector SWOT

CHAPTER 5 OVARIAN CANCER DRUGS MARKET: PIPELINE INTELLIGENCE

5.1. Pipeline Landscape

5.1.1 Leading Drugs in Development

5.1.2 Key R&D Trends

5.2 Key R&D Trends

5.3 Pipeline Landscape

5.3.1 Late Stage Pipeline and Sales Forecast

5.4 Clinical Profiles of Disruptive Drugs

5.5 Global Pipeline Forecast

CHAPTER 6 COMPANY PROFILES

6.1 AstraZeneca

6.1.1 Company Overview

6.1.2 Current Product Portfolio

6.1.3 Product Forecast Sales Through 2022

6.1.4 Strategic Initiatives

6.1.4.1 Key Company News Flow

6.1.5 Pipeline Analysis & Overview

6.1.6 SWOT

6.2 Roche/ Genentech

6.2.1 Company Overview

6.2.2 Current Product Portfolio

6.2.3 Product Forecast Sales Through 2022

6.2.4 Strategic Initiatives

6.2.4.1 Key Company News Flow

6.2.5 Pipeline Analysis & Overview

6.2.6 SWOT

6.3 Tesaro

6.3.1 Company Overview

- 6.3.2 Current Product Portfolio
- 6.3.3 Product Forecast Sales Through 2022
- 6.3.4 Strategic Initiatives
 - 6.3.4.1 Key Company News Flow
- 6.3.5 Pipeline Analysis & Overview
- 6.3.6 SWOT

- 6.4 Clovis Oncology
 - 6.4.1 Company Overview
 - 6.4.2 Current Product Portfolio
 - 6.4.3 Product Forecast Sales Through 2022
 - 6.4.4 Strategic Initiatives
 - 6.4.4.1 Key Company News Flow
 - 6.4.5 Pipeline Analysis & Overview
 - 6.4.6 SWOT

CHAPTER 7 MARKET OUTLOOK

- 7.1 What the Future Holds
- 7.2 The Winners and Losers
 - 7.2.1 Winners
 - 7.2.2 Losers
- 7.3 Emerging Companies & Technology Platforms
- 7.4 The Road Ahead

List Of Tables

LIST OF TABLES

TABLE 1	Stages of Ovarian Cancer and Five-Year Survival Rate
TABLE 2	Type of Patients based on Response to Platinum-based Chemotherapy
TABLE 3	Epidemiology of Ovarian Cancer (2016)
TABLE 4	Marketed Drugs for Ovarian Cancer
TABLE 5	Sales by Therapeutic Class, in \$ million, 2016 - 2022
TABLE 6	PARP Inhibitors Drug Class, Sales (2016 - 2022)
TABLE 7	Angiogenesis Inhibitors Drug Class, Sales (2016 - 2022)
TABLE 8	PD-L1 Inhibitors Drug Class, Sales (2016 - 2022)
TABLE 9	Sales Performance by Geographic Markets, in \$ million, 2016 - 2022
TABLE 10	U.S. Sales by Drug Class (2016 - 2022)
TABLE 11	U.K. Sales by Drug Class (2016 - 2022)
TABLE 12	Germany, Sales by Drug Class (2016 - 2022)
TABLE 13	France, Sales by Drug Class (2016 - 2022)
TABLE 14	Italy, Sales by Drug Class (2016 - 2022)
TABLE 15	Spain, by Drug Class (2016 - 2022)
TABLE 16	Japan, Sales by Drug Class (2016 - 2022)
TABLE 17	Patent Expiry Analysis
TABLE 18	Avastin (bevacizumab) Biosimilars Across Various Indications
TABLE 19	R&D Pipeline Overview – Leading Drugs
TABLE 20	Late Stage Pipeline Analysis
TABLE 21	Bavencio (avelumab)
TABLE 22	VB-111 (ofranergene obadenovec)
TABLE 23	Tecentriq (atezolizumab)
TABLE 24	IMGN853 (mirvetuximab soravtansine)
TABLE 25	Pipeline Forecast
TABLE 26	AstraZeneca Product Forecast Sales (2016 - 2022)
TABLE 27	Roche Product Forecast Sales (2016 - 2022)
TABLE 28	Tesaro Product Forecast Sales (2016 - 2022)
TABLE 29	Clovis Oncology- Product Forecast Sales (2016 - 2022)

List Of Figures

LIST OF FIGURES

- FIG. 1 Market Research Process
- FIG. 2 Information Procurement
- FIG. 3 Primary Research Pattern
- FIG. 4 Market Research Approaches
- FIG. 5 Value Chain based Sizing & Forecasting
- FIG. 6 QFD Modelling for Market Share Assessment
- FIG. 7 U.S. - Ovarian Cancer Incidence and Mortality Trends
- FIG. 8 U.S. - Age Standardized Trends for Ovarian Cancer
- FIG. 9 EU5 Ovarian Cancer Incidence Trends
- FIG. 10 U.K. - Ovarian Cancer Incidence and Mortality Trends
- FIG. 11 Germany - Ovarian Cancer Incidence and Mortality Trends
- FIG. 12 Therapeutic Class, Market Share Distribution, 2016 - 2022
- FIG. 13 PARP Inhibitors, Market Share Distribution, 2016 - 2022
- FIG. 14 Market Size, by Country, 2016 - 2022
- FIG. 15 Market Shares Distribution, by Company (2016 - 2022)
- FIG. 16 India- Ovarian Cancer Prevalence Trends
- FIG. 17 Ovarian Cancer Sector SWOT
- FIG. 18 AstraZeneca Ovarian Cancer Sales Forecast
- FIG. 19 AstraZeneca SWOT Analysis
- FIG. 20 Roche Ovarian Cancer Sales Forecast
- FIG. 21 Roche SWOT Analysis
- FIG. 22 Tesaro Ovarian Cancer Sales Forecast
- FIG. 23 Tesaro SWOT Analysis
- FIG. 24 Clovis Oncology Ovarian Cancer Sales Forecast
- FIG. 25 Clovis Oncology SWOT Analysis

I would like to order

Product name: Ovarian Cancer Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (PARP, PD-L1 Inhibitors , Angiogenesis), By Major Markets (U.S., U.K., Germany, Spain, Italy, France, Japan), And Segment Forecasts, 2016 - 2022

Product link: <https://marketpublishers.com/r/ODE5778F46DEN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ODE5778F46DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970